EurekaMag.com logo
+ Site Statistics
References:
53,623,987
Abstracts:
29,492,080
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Treatment of NT2 cells with valproic acid, trichostatin A, or aza - 2 - deoxycytidine decreases Reelin promoter methylation and increases mRNA expression



Treatment of NT2 cells with valproic acid, trichostatin A, or aza - 2 - deoxycytidine decreases Reelin promoter methylation and increases mRNA expression



Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 313 5



An approximate 50% reduction in reelin mRNA and protein levels have been detected in post-mortem tissue of patients diagnosed with schizophrenia in all brain areas studied to date, including several cortical regions, hippocampus, and cerebellum, which is not attributable to neuronal loss. One potential mechanism of this deficit is hypermethylation of cytosines in the promoter region of the reelin gene. Cytosine hypermethylation could promote histone deacetylation, thereby inducing a closed chromatin state and repressing transcription. In support of this, the histone deacetylase inhibitor (HDAC) valproic acid (VPA) has proven beneficial as an adjunctive treatment in schizophrenia. We previously demonstrated that treatment of NT2 neuronal precursor cells with the HDAC inhibitors valproic acid, trichostatin A (TSA), or the cytosine analog aza-2'-deoxycytidine (AZA), increases reelin mRNA expression. In the current study, we show that treatment of NT2 cells with VPA (5 mM for 48 hrs), TSA (0.3 muM for 24 hrs), or AZA (5 muM for 72 hrs) significantly decreases the number of methylated cytosines in the reelin promoter region relative to untreated NT2 cells. The reduction of reelin promoter cytosine methylation by AZA is consistent with the hypothesis that decreasing methylation increases mRNA expression via a reduction in HDAC activity. Interestingly, the VPA-and TSA-induced reduction of reelin promoter cytosine methylation suggest that DNA demethylase activity is facilitated by histone deacetylase inhibition. The data suggest that HDACs which attenuate promoter methylation are candidates for a new generation of therapeutics in the treatment of schizophrenia.

(PDF 0-2 workdays service: $29.90)

Accession: 035980545

Download citation: RISBibTeXText



Related references

Transcriptional reactivation of murine cytomegalovirus ie gene expression by 5-aza-2'-deoxycytidine and trichostatin A in latently infected cells despite lack of methylation of the major immediate-early promoter. Journal of General Virology 88(Pt 4): 1097-1102, 2007

Exposure of human AML cells to 5-aza-2-deoxycytidine alone or in combination with trichostatin A induces p21CIP1 in the absence of dense promoter methylation. Blood 102(11): 852a, November 16, 2003

The effects of 5-aza-2'- deoxycytidine and trichostatin A on gene expression and DNA methylation status in cloned bovine blastocysts. Cellular Reprogramming 13(4): 297-306, 2011

Effects of 5-Aza-2'-deoxycytidine and trichostatin A on DNA methylation and expression of hMLH1 in ovarian cancer cell line COC1/DDP. Ai Zheng 27(12): 1251-1255, 2010

Dnmt1 antisense treatment increases the expression of reelin mRNA in primary cultures of mouse. Society for Neuroscience Abstract Viewer & Itinerary Planner : Abstract No 774 5, 2003

Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells. Nucleosides, Nucleotides & Nucleic Acids 30(12): 1214-1222, 2012

Effects of 5-Aza-2'-deoxycytidine and trichostatin A on P16, hMLH1 and MGMT genes and DNA methylation in human gastric cancer cells. Zhonghua Wei Chang Wai Ke Za Zhi 12(5): 494-497, 2010

Electrical stimulation in vivo increases the expression of proenkephalin mRNA and decreases the expression of prodynorphin mRNA in rat hippocampal granule cells. Proceedings of the National Academy of Sciences of the United States of America 85(9): 3226-3230, 1988

Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Molecular Cancer Therapeutics 4(3): 477-486, 2005

Timing is everything: order of administration of 5-aza 2' deoxycytidine, trichostatin A and tamoxifen changes estrogen receptor mRNA expression and cell sensitivity. Cancer Letters 275(2): 178-184, 2008

HDAC inhibitors, trichostatin A and valproic acid, increase Ecadherin and vimentin expression but inhibit migration and invasion of cholangiocarcinoma cells. Oncology Reports, 2018

Trichostatin A and 5 Aza-2' deoxycytidine decrease estrogen receptor mRNA stability in ER positive MCF7 cells through modulation of HuR. Breast Cancer Research and Treatment 111(1): 15-25, 2007

Growth inhibition of human cancer cells by 5-aza-2'-deoxycytidine does not correlate with its effects on INK4a/ARF expression or initial promoter methylation status. Molecular Cancer Therapeutics 8(4): 779-785, 2009

Synergistic induction of NY-ESO-1 antigen expression by a novel histone deacetylase inhibitor, valproic acid, with 5-aza-2'-deoxycytidine in glioma cells. Journal of Neuro-Oncology 92(1): 15-22, 2008

Histone deacetylase inhibitors trichostatin A and valproic acid induce cell cycle arrest and p21 expression in immortalized human endometrial stromal cells. European Journal of Obstetrics, Gynecology, and Reproductive Biology 137(2): 198-203, 2007